Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?

Abstract

The childhood forms of polycystic kidney disease are autosomal recessive polycystic kidney disease and nephronophthisis. In animal models of these diseases, characterised by a defect in urine concentration progressing to renal failure, the selective vasopressin receptor type 2 antagonist OPC-31260 halted the progression or even caused regression of the established disease. Vasopressin receptor type 2 antagonists should proceed to clinical trial for these polycystic kidney diseases.

• animal models
• autosomal recessive polycystic kidney disease
• nephronophthisis
• OPC-31260
• polycystic kidney disease
• V₂ receptor antagonist